share_log

UBS Maintains Buy on Treace Medical Concepts, Lowers Price Target to $16

UBS Maintains Buy on Treace Medical Concepts, Lowers Price Target to $16

瑞银维持对Treace Medical Concepts的买入,将目标股价下调至16美元
Benzinga ·  05/08 09:56

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:TMCI) with a Buy and lowers the price target from $17 to $16.

瑞银分析师丹妮尔·安塔尔菲维持Treace Medical Concepts(纳斯达克股票代码:TMCI)的买入并将目标股价从17美元下调至16美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发